210 related articles for article (PubMed ID: 30239803)
1. Clinical, Biochemical, and Genetic Characteristics of "Nonclassic" Apparent Mineralocorticoid Excess Syndrome.
Tapia-Castillo A; Baudrand R; Vaidya A; Campino C; Allende F; Valdivia C; Vecchiola A; Lagos CF; Fuentes CA; Solari S; Martínez-Aguayo A; García H; Carvajal CA; Fardella CE
J Clin Endocrinol Metab; 2019 Feb; 104(2):595-603. PubMed ID: 30239803
[TBL] [Abstract][Full Text] [Related]
2. Serum Cortisol and Cortisone as Potential Biomarkers of Partial 11β-Hydroxysteroid Dehydrogenase Type 2 Deficiency.
Carvajal CA; Tapia-Castillo A; Valdivia CP; Allende F; Solari S; Lagos CF; Campino C; Martínez-Aguayo A; Vecchiola A; Pinochet C; Godoy C; Iturrieta V; Baudrand R; Fardella CE
Am J Hypertens; 2018 Jul; 31(8):910-918. PubMed ID: 29617893
[TBL] [Abstract][Full Text] [Related]
3. [From gene to disease; 'apparent mineralocorticoid excess' syndrome, a syndrome with an apparent excess of mineral corticoids].
Levtchenko EN; Deinum J; Knoers NV; Hermus AR; Monnens LA; Lenders JW
Ned Tijdschr Geneeskd; 2007 Mar; 151(12):692-4. PubMed ID: 17447595
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of exosomal miR-192-5p and miR-204-5p in subjects with nonclassic apparent mineralocorticoid excess.
Tapia-Castillo A; Guanzon D; Palma C; Lai A; Barros E; Allende F; Vecchiola A; Fardella CE; Salomón C; Carvajal CA
J Transl Med; 2019 Nov; 17(1):392. PubMed ID: 31775784
[TBL] [Abstract][Full Text] [Related]
5. Apparent mineralocorticoid excess syndrome: an overview.
Palermo M; Quinkler M; Stewart PM
Arq Bras Endocrinol Metabol; 2004 Oct; 48(5):687-96. PubMed ID: 15761540
[TBL] [Abstract][Full Text] [Related]
6. Classic and Nonclassic Apparent Mineralocorticoid Excess Syndrome.
Carvajal CA; Tapia-Castillo A; Vecchiola A; Baudrand R; Fardella CE
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 31909799
[TBL] [Abstract][Full Text] [Related]
7. Detection of Urinary Exosomal HSD11B2 mRNA Expression: A Useful Novel Tool for the Diagnostic Approach of Dysfunctional 11β-HSD2-Related Hypertension.
De Santis D; Castagna A; Danese E; Udali S; Martinelli N; Morandini F; Veneri M; Bertolone L; Olivieri O; Friso S; Pizzolo F
Front Endocrinol (Lausanne); 2021; 12():681974. PubMed ID: 34497581
[TBL] [Abstract][Full Text] [Related]
8. Apparent mineralocorticoid excess syndrome: report of one family with three affected children.
Al-Harbi T; Al-Shaikh A
J Pediatr Endocrinol Metab; 2012; 25(11-12):1083-8. PubMed ID: 23329753
[TBL] [Abstract][Full Text] [Related]
9. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.
Atanasov AG; Ignatova ID; Nashev LG; Dick B; Ferrari P; Frey FJ; Odermatt A
J Am Soc Nephrol; 2007 Apr; 18(4):1262-70. PubMed ID: 17314322
[TBL] [Abstract][Full Text] [Related]
10. Apparent Mineralocorticoid Excess by a Novel Mutation and Epigenetic Modulation by HSD11B2 Promoter Methylation.
Pizzolo F; Friso S; Morandini F; Antoniazzi F; Zaltron C; Udali S; Gandini A; Cavarzere P; Salvagno G; Giorgetti A; Speziali G; Choi SW; Olivieri O
J Clin Endocrinol Metab; 2015 Sep; 100(9):E1234-41. PubMed ID: 26126204
[TBL] [Abstract][Full Text] [Related]
11. Apparent mineralocorticoid excess (AME) syndrome.
Parvez Y; Sayed OE
Indian Pediatr; 2013 Apr; 50(4):416-8. PubMed ID: 23665601
[TBL] [Abstract][Full Text] [Related]
12. Apparent mineralocorticoid excess syndrome in a Brazilian boy caused by the homozygous missense mutation p.R186C in the HSD11B2 gene.
Coeli FB; Ferraz LF; Lemos-Marini SH; Rigatto SZ; Belangero VM; de-Mello MP
Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1277-81. PubMed ID: 19169481
[TBL] [Abstract][Full Text] [Related]
13. Apparent mineralocorticoid excess caused by novel compound heterozygous mutations in HSD11B2 and characterized by early-onset hypertension and hypokalemia.
Fan P; Lu YT; Yang KQ; Zhang D; Liu XY; Tian T; Luo F; Wang LP; Ma WJ; Liu YX; Zhang HM; Song L; Cai J; Lou Y; Zhou XL
Endocrine; 2020 Dec; 70(3):607-615. PubMed ID: 32816205
[TBL] [Abstract][Full Text] [Related]
14. Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency.
Yau M; Haider S; Khattab A; Ling C; Mathew M; Zaidi S; Bloch M; Patel M; Ewert S; Abdullah W; Toygar A; Mudryi V; Al Badi M; Alzubdi M; Wilson RC; Al Azkawi HS; Ozdemir HN; Abu-Amer W; Hertecant J; Razzaghy-Azar M; Funder JW; Al Senani A; Sun L; Kim SM; Yuen T; Zaidi M; New MI
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11248-E11256. PubMed ID: 29229831
[TBL] [Abstract][Full Text] [Related]
15. Apparent mineralocorticoid excess in Israel: a case series and literature review.
Lebel A; Ben Shalom E; Mokatern R; Halevy R; Zehavi Y; Magen D
Eur J Endocrinol; 2024 May; 190(5):347-353. PubMed ID: 38652803
[TBL] [Abstract][Full Text] [Related]
16. Apparent Mineralocorticoid Excess in the Pediatric Population: Report of a Novel Pathogenic Variant of the 11β-HSD2 Gene and Systematic Review of the Literature.
Adamidis A; Cantas-Orsdemir S; Tsirka A; Abbott MA; Visintainer P; Tonyushkina K
Pediatr Endocrinol Rev; 2019 Mar; 16(3):335-358. PubMed ID: 30888125
[TBL] [Abstract][Full Text] [Related]
17. Novel metabolomic profile of subjects with non-classic apparent mineralocorticoid excess.
Tapia-Castillo A; Carvajal CA; López-Cortés X; Vecchiola A; Fardella CE
Sci Rep; 2021 Aug; 11(1):17156. PubMed ID: 34433879
[TBL] [Abstract][Full Text] [Related]
18. Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess.
Whorwood CB; Stewart PM
J Hypertens Suppl; 1996 Dec; 14(5):S19-24. PubMed ID: 9120678
[TBL] [Abstract][Full Text] [Related]
19. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
Ferrari P; Lovati E; Frey FJ
J Hypertens; 2000 Mar; 18(3):241-8. PubMed ID: 10726708
[TBL] [Abstract][Full Text] [Related]
20. Does kidney transplantation normalise cortisol metabolism in apparent mineralocorticoid excess syndrome?
Palermo M; Delitala G; Sorba G; Cossu M; Satta R; Tedde R; Pala A; Shackleton CH
J Endocrinol Invest; 2000; 23(7):457-62. PubMed ID: 11005270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
